Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Current Leases (2020 - 2025)

Arcutis Biotherapeutics has reported Current Leases over the past 6 years, most recently at $842000.0 for Q1 2025.

  • Quarterly results put Current Leases at $842000.0 for Q1 2025, up 11.38% from a year ago — trailing twelve months through Mar 2025 was $842000.0 (up 11.38% YoY), and the annual figure for FY2024 was $820000.0, up 11.56%.
  • Current Leases for Q1 2025 was $842000.0 at Arcutis Biotherapeutics, up from $820000.0 in the prior quarter.
  • Over the last five years, Current Leases for ARQT hit a ceiling of $842000.0 in Q1 2025 and a floor of $106000.0 in Q2 2021.
  • Median Current Leases over the past 5 years was $685500.0 (2023), compared with a mean of $627750.0.
  • Biggest five-year swings in Current Leases: surged 856.25% in 2021 and later grew 11.38% in 2025.
  • Arcutis Biotherapeutics' Current Leases stood at $433000.0 in 2021, then soared by 51.73% to $657000.0 in 2022, then grew by 11.87% to $735000.0 in 2023, then rose by 11.56% to $820000.0 in 2024, then increased by 2.68% to $842000.0 in 2025.
  • The last three reported values for Current Leases were $842000.0 (Q1 2025), $820000.0 (Q4 2024), and $798000.0 (Q3 2024) per Business Quant data.